DAFNA Capital Management LLC Acquires 1,160,666 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

DAFNA Capital Management LLC boosted its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 85.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,511,374 shares of the company's stock after buying an additional 1,160,666 shares during the quarter. DAFNA Capital Management LLC owned approximately 1.14% of Lineage Cell Therapeutics worth $1,262,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Fort Sheridan Advisors LLC lifted its stake in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock worth $28,000 after acquiring an additional 23,000 shares during the period. HighTower Advisors LLC increased its position in shares of Lineage Cell Therapeutics by 49.5% during the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock worth $29,000 after buying an additional 19,100 shares during the period. Atria Wealth Solutions Inc. acquired a new position in Lineage Cell Therapeutics in the fourth quarter valued at $29,000. SG Americas Securities LLC boosted its position in Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock valued at $35,000 after acquiring an additional 18,053 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Lineage Cell Therapeutics by 33.0% during the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company's stock worth $48,000 after acquiring an additional 23,527 shares during the period. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Stock Performance

Shares of Lineage Cell Therapeutics stock traded down $0.03 during trading on Friday, hitting $0.44. The company's stock had a trading volume of 1,328,452 shares, compared to its average volume of 1,311,854. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.37 and a 52 week high of $1.17. The company has a market capitalization of $96.98 million, a PE ratio of -3.67 and a beta of 1.21. The company has a fifty day simple moving average of $0.47 and a two-hundred day simple moving average of $0.63.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LCTX shares. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. B. Riley reduced their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Finally, D. Boral Capital restated a "buy" rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $4.20.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.